Cargando…

Treatment outcomes of patients with drug-sensitive tuberculosis under community-based versus facility-based directly observed treatment, short course strategy in Southwest Ethiopia: a prospective cohort study

OBJECTIVE: To compare tuberculosis (TB) treatment outcomes and associated factors among patients attending community-based versus facility-based directly observed treatment, short course (DOTS). DESIGN: A prospective cohort study. SETTING: The study was conducted in Southwest Ethiopia. There were se...

Descripción completa

Detalles Bibliográficos
Autores principales: Ereso, Berhane Megerssa, Sagbakken, Mette, Gradmann, Christoph, Yimer, Solomon Abebe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296762/
https://www.ncbi.nlm.nih.gov/pubmed/34290068
http://dx.doi.org/10.1136/bmjopen-2020-048369
_version_ 1783725709864206336
author Ereso, Berhane Megerssa
Sagbakken, Mette
Gradmann, Christoph
Yimer, Solomon Abebe
author_facet Ereso, Berhane Megerssa
Sagbakken, Mette
Gradmann, Christoph
Yimer, Solomon Abebe
author_sort Ereso, Berhane Megerssa
collection PubMed
description OBJECTIVE: To compare tuberculosis (TB) treatment outcomes and associated factors among patients attending community-based versus facility-based directly observed treatment, short course (DOTS). DESIGN: A prospective cohort study. SETTING: The study was conducted in Southwest Ethiopia. There were seven hospitals (five primary, one general and one specialised), 120 health centres and 494 health posts. PARTICIPANTS: A total of 1161 individuals consented to participate in the study (387 patients under community-based DOTS (CB-DOTS) and 774 patients under facility-based DOTS (FB-DOTS)). Individuals who could not respond to the questions, mentally or critically ill patients, and those less than 15 years old, were excluded from the study. PRIMARY OUTCOME MEASURE: TB treatment outcomes were compared among patients under CB-DOTS versus FB-DOTS. Risk ratio (RR), risk difference (RD) and confidence interval (CI) were calculated among the study groups. In addition, χ(2) or Fisher’s exact tests were used to compare group differences, with a p value of <0.05 considered statistically significant. RESULTS: Patients who opted for CB-DOTS were more likely to be cured by 12% than those who opted for FB-DOTS (RR=1.12, 95% CI=0.96 to 1.30). Patients under CB-DOTS had a lesser risk of death (RR=0.93, 95% CI=0.49 to 1.77) and a lower risk of treatment failure (RR=0.86, 95% CI=0.22 to 3.30) than those under FB-DOTS. Furthermore, patients who opted for CB-DOTS were less likely to have a positive sputum smear result at the end of the treatment period (p=0.042) compared with their counterparts. CONCLUSION: The study showed that CB-DOTS is more effective than FB-DOTS in terms of improving cure rate and sputum conversion rate, as well as lowering treatment failure rate. Our findings show the need for scaling up and a further decentralisation of CB-DOTS approach to improve access to TB treatment service for the rural community.
format Online
Article
Text
id pubmed-8296762
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-82967622021-08-12 Treatment outcomes of patients with drug-sensitive tuberculosis under community-based versus facility-based directly observed treatment, short course strategy in Southwest Ethiopia: a prospective cohort study Ereso, Berhane Megerssa Sagbakken, Mette Gradmann, Christoph Yimer, Solomon Abebe BMJ Open Public Health OBJECTIVE: To compare tuberculosis (TB) treatment outcomes and associated factors among patients attending community-based versus facility-based directly observed treatment, short course (DOTS). DESIGN: A prospective cohort study. SETTING: The study was conducted in Southwest Ethiopia. There were seven hospitals (five primary, one general and one specialised), 120 health centres and 494 health posts. PARTICIPANTS: A total of 1161 individuals consented to participate in the study (387 patients under community-based DOTS (CB-DOTS) and 774 patients under facility-based DOTS (FB-DOTS)). Individuals who could not respond to the questions, mentally or critically ill patients, and those less than 15 years old, were excluded from the study. PRIMARY OUTCOME MEASURE: TB treatment outcomes were compared among patients under CB-DOTS versus FB-DOTS. Risk ratio (RR), risk difference (RD) and confidence interval (CI) were calculated among the study groups. In addition, χ(2) or Fisher’s exact tests were used to compare group differences, with a p value of <0.05 considered statistically significant. RESULTS: Patients who opted for CB-DOTS were more likely to be cured by 12% than those who opted for FB-DOTS (RR=1.12, 95% CI=0.96 to 1.30). Patients under CB-DOTS had a lesser risk of death (RR=0.93, 95% CI=0.49 to 1.77) and a lower risk of treatment failure (RR=0.86, 95% CI=0.22 to 3.30) than those under FB-DOTS. Furthermore, patients who opted for CB-DOTS were less likely to have a positive sputum smear result at the end of the treatment period (p=0.042) compared with their counterparts. CONCLUSION: The study showed that CB-DOTS is more effective than FB-DOTS in terms of improving cure rate and sputum conversion rate, as well as lowering treatment failure rate. Our findings show the need for scaling up and a further decentralisation of CB-DOTS approach to improve access to TB treatment service for the rural community. BMJ Publishing Group 2021-07-21 /pmc/articles/PMC8296762/ /pubmed/34290068 http://dx.doi.org/10.1136/bmjopen-2020-048369 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Public Health
Ereso, Berhane Megerssa
Sagbakken, Mette
Gradmann, Christoph
Yimer, Solomon Abebe
Treatment outcomes of patients with drug-sensitive tuberculosis under community-based versus facility-based directly observed treatment, short course strategy in Southwest Ethiopia: a prospective cohort study
title Treatment outcomes of patients with drug-sensitive tuberculosis under community-based versus facility-based directly observed treatment, short course strategy in Southwest Ethiopia: a prospective cohort study
title_full Treatment outcomes of patients with drug-sensitive tuberculosis under community-based versus facility-based directly observed treatment, short course strategy in Southwest Ethiopia: a prospective cohort study
title_fullStr Treatment outcomes of patients with drug-sensitive tuberculosis under community-based versus facility-based directly observed treatment, short course strategy in Southwest Ethiopia: a prospective cohort study
title_full_unstemmed Treatment outcomes of patients with drug-sensitive tuberculosis under community-based versus facility-based directly observed treatment, short course strategy in Southwest Ethiopia: a prospective cohort study
title_short Treatment outcomes of patients with drug-sensitive tuberculosis under community-based versus facility-based directly observed treatment, short course strategy in Southwest Ethiopia: a prospective cohort study
title_sort treatment outcomes of patients with drug-sensitive tuberculosis under community-based versus facility-based directly observed treatment, short course strategy in southwest ethiopia: a prospective cohort study
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296762/
https://www.ncbi.nlm.nih.gov/pubmed/34290068
http://dx.doi.org/10.1136/bmjopen-2020-048369
work_keys_str_mv AT eresoberhanemegerssa treatmentoutcomesofpatientswithdrugsensitivetuberculosisundercommunitybasedversusfacilitybaseddirectlyobservedtreatmentshortcoursestrategyinsouthwestethiopiaaprospectivecohortstudy
AT sagbakkenmette treatmentoutcomesofpatientswithdrugsensitivetuberculosisundercommunitybasedversusfacilitybaseddirectlyobservedtreatmentshortcoursestrategyinsouthwestethiopiaaprospectivecohortstudy
AT gradmannchristoph treatmentoutcomesofpatientswithdrugsensitivetuberculosisundercommunitybasedversusfacilitybaseddirectlyobservedtreatmentshortcoursestrategyinsouthwestethiopiaaprospectivecohortstudy
AT yimersolomonabebe treatmentoutcomesofpatientswithdrugsensitivetuberculosisundercommunitybasedversusfacilitybaseddirectlyobservedtreatmentshortcoursestrategyinsouthwestethiopiaaprospectivecohortstudy